National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "2. Priority Setting for Health Related Investments: A Review of Methods." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
17
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

2
Priority Setting for Health Related Investments: A Review of Methods

One of the first tasks in ranking and choosing among health related investments is selection of an appropriate method. Several methods have been applied successfully to problems conceptually similar to that of setting priorities for accelerated development of vaccines. Examples of these problems include setting priorities for resource allocation to medical technologies; setting priorities in medical research; selecting chemicals for toxicity testing; and selecting hazardous waste sites for clean-up. The methods themselves draw from techniques in systems analysis, decision analysis, and cost-benefit analysis. (Selected applications are described in Appendix A.)

Methods for Project Ranking and Selection

The five methods considered for use in ranking vaccine candidates are described below. They are (1) multiattribute accounting; (2) multiattribute scoring; (3) decision analysis with multiple objectives; (4) cost-effectiveness and cost-utility analysis; and (5) benefit-cost analysis. They differ from one another in several ways, most notably the extent of quantification demanded and the extent to which the ranking procedure is fashioned to reflect particular normative rules. The last part of this chapter considers some general issues in implementing any ranking methodology, including sources of estimates, appropriate use of sequential or “lexicographic” methods, problems of interdependence among projects, and the “portfolio” question.

Multiattribute Accounting

The ranking method requiring the least quantification and demanding the fewest normative assumptions is multiattribute accounting. This approach arrays the performance of each alternative on each valued objective, without attempting to produce an explicit overall score for each alternative. In deferring the final ranking to decision makers or consensus panels, multiattribute accounting differs from the other

Page
17
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 17

OCR for page 18

OCR for page 19

OCR for page 20

OCR for page 21

OCR for page 22

OCR for page 23

OCR for page 24

OCR for page 25

OCR for page 26

OCR for page 27